Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November

Audio By Carbonatix

ALAMEDA, Calif.--(BUSINESS WIRE)--Nov 6, 2025--

Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in November:

• Guggenheim 2 nd Annual Healthcare Innovation Conference: Exelixis is scheduled to present at 10:30 a.m. ET / 7:30 a.m. PT on Monday, November 10 in Boston.
• Stifel 2025 Healthcare Conference: Exelixis is scheduled to present at 8:40 a.m. ET / 5:40 a.m. PT on Tuesday, November 11 in New York City.

To access the webcast links, log onto www.exelixis.com and proceed to the Event Calendar page under the Investors & News heading. Replays will also be available at the same location for at least 30 days.

About Exelixis

Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by drug discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules and biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our investigational programs and extend the impact of our flagship commercial product, CABOMETYX ® (cabozantinib). Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission to help cancer patients recover stronger and live longer, visit www.exelixis.com, follow @ExelixisInc on X (Twitter), like Exelixis, Inc. on Facebook and follow Exelixis on LinkedIn.

Exelixis, the Exelixis logo and CABOMETYX are registered U.S. trademarks.

View source version on businesswire.com:https://www.businesswire.com/news/home/20251106310715/en/

CONTACT: Investors Contact:

Varant Shirvanian

Director, Investor Relations

Exelixis, Inc.

650-837-7917

[email protected] Contact:

Hal Mackins

For Exelixis, Inc.

415-994-0040

[email protected]

KEYWORD: MASSACHUSETTS CALIFORNIA NEW YORK UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: BIOTECHNOLOGY HEALTH ONCOLOGY

SOURCE: Exelixis, Inc.

Copyright Business Wire 2025.

PUB: 11/06/2025 04:05 PM/DISC: 11/06/2025 04:05 PM

http://www.businesswire.com/news/home/20251106310715/en